Introduction:
The biosimilar market in Ireland is rapidly growing, in line with global trends towards increased biosimilar adoption. In 2021, the global biosimilar market was valued at $5.2 billion and is expected to reach $42.7 billion by 2026, with a CAGR of 52.0% during the forecast period.
Spotlight Top 50 Biosimilar Trial Sites in Ireland 2026
1. St. James’s Hospital, Dublin
St. James’s Hospital is one of the leading biosimilar trial sites in Ireland, conducting research on a wide range of biosimilar products. With a strong track record in clinical trials, St. James’s Hospital plays a key role in advancing biosimilar development in the country.
2. Mater Misericordiae University Hospital, Dublin
Mater Misericordiae University Hospital is another top biosimilar trial site in Ireland, known for its expertise in conducting high-quality clinical trials. The hospital’s collaboration with pharmaceutical companies has led to significant advancements in biosimilar research.
Insights:
The biosimilar market in Ireland is poised for significant growth in the coming years, driven by increasing demand for cost-effective treatment options and a favorable regulatory environment. By focusing on collaboration between trial sites, pharmaceutical companies, and regulatory bodies, Ireland can further solidify its position as a key player in the global biosimilar market. With a strong infrastructure for clinical research and a skilled workforce, Ireland is well-positioned to capitalize on the growing opportunities in the biosimilar sector.
Related Analysis: View Previous Industry Report
